QLUPOD AG: Successful Trademark Registration in the USA – Paving the Way for Market Entry

[ Fotos /PDFs ]

Herisau (pta015/06.02.2025/10:44 UTC+1)

Published on February 6, 2025, by Qlupod AG

Herisau, Switzerland – February 6, 2025 – QluPod AG (www.qlupod.com) is

pleased to announce that the QLUPOD trademark has been successfully registered

in the United States. The trademark registration, officially announced on February

5, 2025, in the U.S. Trademark Official Gazette under the number 79393220,

marks a significant step towards the company's expansion into the U.S. market.

This success represents a major milestone in Qlupod AG's international growth

strategy and paves the way for the launch of its innovative health solutions –

particularly the QluPod device and accompanying apps – in the United States.

Important Step for Expansion into the U.S. Market

With the trademark registration in the U.S., Qlupod is now well-positioned to

establish its health-monitoring technology in the world's largest medical device

market. "Achieving trademark registration in the U.S. is a key milestone for

Qlupod, opening up new opportunities in the global competition. We are now ready

to offer the QluPod and our app solutions in the U.S., thus improving local

healthcare," said Nikola Trajanov, Interim CEO of Qlupod AG.

QluPod – Innovative and User-Friendly

The QluPod device enables users to monitor their health data in real time and

share it directly with doctors or caregivers. It measures the five most important

vital signs: heart rate, blood oxygen saturation, body temperature, ECG, and

blood pressure. The compact device is CE-certified and TÜV-tested, ensuring the

highest quality and safety standards. With the QluPod app, users can store their

data and ensure continuous monitoring, which is especially valuable for

telemedicine and patient care.

Future Prospects for the U.S.

The U.S. market launch of QluPod is closely tied to the company's ongoing

development and collaboration with strategic partners in the international market.

"Expanding into the U.S. is the next logical step for us. The U.S. market offers

tremendous growth opportunities, and we are confident that the QluPod can make

a significant contribution to improving digital healthcare," Trajanov added.

About Qlupod:

Qlupod AG is a start-up company in the field of telemedicine and develops

innovative solutions to make patient care efficient and cost-effective. With the

QluPod device and the associated software, the company is endeavouring to shape

the future of healthcare. The offering is aimed at hospitals, care facilities, medical

professionals and private individuals who want to monitor their health

independently.

For more information about Qlupod AG and our products, please visit our website

at www.qlupod.com.Disclaimer:

This publication constitutes neither an offer to sell nor a solicitation to buy

securities. Insofar as this document contains forward-looking statements, these

do not represent facts and are characterised by the words "expect", "believe",

"estimate", "intend", "aim", "assume" and similar expressions. These statements

express the intentions, opinions or current expectations and assumptions of

Qlupod AG and are based on current plans, estimates and forecasts which Qlupod

AG has made to the best of its knowledge, but do not claim to be correct in the

future. Forward-looking statements are subject to risks and uncertainties that are

difficult to predict and are generally beyond the control of Qlupod AG. It should

be noted that actual events or developments may differ materially from the events

and developments expressed or implied by such forward-looking statements.

(end)

Emitter:	QLUPOD AG Bahnhofstrasse 23 9100 Herisau Switzerland
Contact Person:	Nikola Trajanov
Phone:	+41 71 510 05 45
E-Mail:	ir@qlupod.com
Website:	qlupod.eu
ISIN(s):	CH1222316429 (Share)
Stock Exchange(s):	-
Other Stock Exchanges:	Regelmaessige Kursfeststellung Schweiz